Abstract
Background The Acute Respiratory Distress Syndrome (ARDS) occurs in response to a variety of insults, and mechanical ventilation is life-saving in this setting, but ventilator induced lung injury can also contribute to the morbidity and mortality in the condition. The Beacon Caresystem is a model-based bedside decision support system using mathematical models tuned to the individual patient’s physiology to advise on appropriate ventilator settings. Personalised approaches using individual patient description may be particularly advantageous in complex patients, including those who are difficult to mechanically ventilate and wean, in particular ARDS.
Methods We will conduct a multi-centre international randomised, controlled, allocation concealed, open, pragmatic clinical trial to compare mechanical ventilation in ARDS patients following application of the Beacon Caresystem to that of standard routine care to investigate whether use of the system results in a reduction in driving pressure across all severities and phases of ARDS.
Discussion Despite 20 years of clinical trial data showing significant improvements in ARDS mortality through mitigation of ventilator induced lung injury, there remains a gap in its personalised application at the bedside. Importantly, the protective effects of higher positive end-expiratory pressure (PEEP) were noted only when there were associated decreases in driving pressure. Hence, the pressures set on the ventilator should be determined by the diseased lungs’ pressure-volume relationship which is often unknown or difficult to determine. Knowledge of extent of recruitable lung could improve the ventilator driving pressure. Hence, personalised management demands the application of mechanical ventilation according to the physiological state of the diseased lung at that time. Hence, there is significant rationale for the development of point-of-care clinical decision support systems which help personalise ventilatory strategy according to the current physiology. Furthermore, the potential for the application of the Beacon Caresystem to facilitate local and remote management of large numbers of ventilated patients (as seen during this COVID-19 pandemic), could change the outcome of mechanically ventilated patients during the course of this and future pandemics.
Trial registration ClinicalTrials.gov identifier (NCT number): NCT04115709
Administrative information Note: the numbers in curly brackets in this protocol refer to SPIRIT checklist item numbers. The order of the items has been modified to group similar items (see http://www.equator-network.org/reporting-guidelines/spirit-2013-statement-defining-standard-protocol-items-for-clinical-trials/).
Competing Interest Statement
JH is chief executive officer for Mermaid Care A/S who manufacture the Beacon Caresystem. SR and DK are minor shareholders and SR is a board member of Mermaid Care A/S who manufacture the Beacon Caresystem.
Clinical Trial
ClinicalTrials.gov identifier (NCT number): NCT04115709
Funding Statement
The European Commission Horizon 2020 Fast Track to Innovation Programme will be providing the research costs for the DeVENT study (Reference EU project 853850 - ECMO-BIOMARKER). The funder had no role in the trial design, collection, management, analysis or interpretation of data, writing of reports or submission for publication.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
In the UK, the study received ethical approval by the London South-East Research Ethics Committee (Ref: 19/LO/1606) on 15 January 2020 with proitocol version 4.0 approved on 16th June 2021. The study protocol was approved by the French Ethics Committee (Comitè de Protection des Personnes Sud Mediterranee III; approved on July 30, 2020 under number2019.12.06 ter_19.11.15.76132) and Medicine Agency (Agence Nationale de Sècuritè du Mèdicament; approved on July 3, 2020 under number 2019-A02610-57-A). The study protocol was approved by the ethics committee of Medical University of Vienna, Austria (EC No. 2056/2019) on 28th April 2020.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵* see acknowledgements
Data Availability
All data will be available on request through the sponsor.
Abbreviations
- Abbreviation / Acronym
- Full Wording
- ABG
- Arterial Blood Gas
- AE
- Adverse Event
- ALPE
- Automatic Lung Parameter Estimation
- APACHE II
- Acute Physiology and Chronic Health Evaluation Score II
- APMIC
- Anaesthesia, Pain Medicine and Intensive Care
- APRV
- Airway Pressure Release Ventilation
- ARDS
- Acute Respiratory Distress Syndrome
- BAL
- Bronchoalveolar lavage
- CI
- Chief Investigator
- CO2
- Carbon Dioxide
- CONSORT
- Consolidated Standards of Reporting Trials
- COVID-19
- Novel Coronavirus Disease 2019
- CRF/eCRF
- Case Report Form/Electronic Case Report Form
- CTU
- Clinical Trials Unit
- DMEC
- Data Monitoring and Ethics Committee
- DNAR
- Do Not Attempt Resuscitation
- ECMO
- Extracorporeal Membrane Oxygenation
- ECCO2R
- ExtraCorporeal Carbon Dioxide Removal
- EQ-5D-5L
- EuroQoL-5 Dimension Questionnaire (5 level version)
- EELV
- End-Expiratory lung Volume
- FE’CO2
- End-tidal CO2 fraction
- FiO2
- Fraction of Inspired Oxygen
- GCP
- Good Clinical Practice
- HADS
- Hospital Anxiety and Depression Score
- HRA
- Health Research Authority
- HRQoL
- Health Related Quality of Life
- ICF
- Informed Consent Form
- ICH
- International Council on Harmonisation
- ICTU
- Imperial Clinical Trials Unit
- ICU
- Intensive Care Unit
- IRAS
- Integrated Research Application System
- MHRA
- Medicines and Healthcare products Regulatory Agency
- MOCA
- The Montreal Cognitive Assessment
- NHS
- National Health Service
- NIHR
- National Institute for Health Research
- NIV
- Non Invasive Ventilation
- NMBD
- Neuromuscular Blocking Drugs
- PaCO2
- Partial Pressure of Carbon Dioxide in arterial blood
- PaO2
- Partial Pressure of Oxygen in arterial blood
- PBW
- Predicted Body Weight
- PEEP
- Positive End Expiratory Pressure
- P/F
- ratio PaO2/FiO2 ratio
- PI
- Principal Investigator
- PIS
- Patient Information Sheet
- PPI
- Patient and Public Involvement
- Pplat
- Plateau Pressure
- PTSD
- Post Traumatic Stress Disorder
- PTSS
- 14 Post Traumatic Stress Syndrome Questionnaire
- RALE
- Radiographic Assessment of Lung Oedema
- REC
- Research Ethics Committee
- RR
- Respiratory Rate
- SAE
- Serious Adverse Event
- SAP
- Statistical Analysis Plan
- SAPS II
- Simplified Acute Physiology Score
- SBT
- Spontaneous Breathing Trial
- SGRQ
- St George’s Respiratory Questionnaire
- SOFA
- Sequential Organ Failure Assessment
- SOPs
- Standard Operating Procedures
- SpO2
- Oxygen Saturation
- SRM
- Study Reference Manual
- TAPSE
- Tricuspid Annular Plane Systolic Excursion
- TIDIeR
- Template for intervention description and replication
- TMF
- Trial Master File
- TMG
- Trial Management Group
- TSC
- Trial Steering Committee
- VCO2
- Carbon Dioxide production
- VILI
- Ventilator Induced Lung Injury
- VO2
- Oxygen Consumption
- Vt
- Tidal Volume